5-HT4 receptor agonist compounds for the treatment of cognitive disorders

Details for Australian Patent Application No. 2010236734 (hide)

Owner Theravance, Inc.

Inventors Beattie, David; Shen, Fei; Smith, Jacqueline A. M.; McKinnell, Robert Murray; Chang, Ray

Agent Davies Collison Cave

Pub. Number AU-A-2010236734

PCT Pub. Number WO2010/120695

Priority 61/292,559 06.01.10 US; 61/168,741 13.04.09 US

Filing date 12 April 2010

Wipo publication date 21 October 2010

International Classifications

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61K 31/454 (2006.01)

A61K 31/4709 (2006.01) - Non-condensed quinolines containing further heterocyclic rings

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

3 November 2011 PCT application entered the National Phase

  PCT publication WO2010/120695 Priority application(s): WO2010/120695

16 February 2012 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name Theravance, Inc., Application No. 2010236734, under INID (54) correct the title to 5-HT4 receptor agonist compounds for treatment of cognitive disorders

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010236740-System and method for enhanced display of "in-network caller" information on a mobile device

2010236732-Methods and apparatus for overlaying content onto a common video stream